Meeting
2018 ASCO Quality Care Symposium
Real-world comparison of biosimilar filgrastim and reference filgrastim in cancer patients receiving chemotherapy.
Authors
Xiaoxue Chen
HealthCore, Inc., Wilmington, DE
Xiaoxue Chen, John Barron, Abiy Agiro, David Joseph Debono, Michael Jordan Fisch
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Big Data Studies; Projects Relating to Equity, Value, and Policy
Track
Projects Relating to Equity, Value and Policy,Big Data Studies
Sub Track
Measuring Value and Costs
Citation
J Clin Oncol 36, 2018 (suppl 30; abstr 85)
DOI
10.1200/JCO.2018.36.30_suppl.85
Abstract #
85
Poster Bd #
J4
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Quality Care Symposium
Real-world utilization and costs with biosimilar and reference filgrastim in patients with breast cancer receiving myelosuppressive chemotherapy in a community oncology setting from 2015 to 2017.
First Author: Robert M. Rifkin
Poster
2024 ASCO Annual Meeting
Medicare reimbursement trends of biological reference agents and their biosimilars.
First Author: John Albaugh
Poster
2023 ASCO Quality Care Symposium
Patient characteristics associated with myelosuppression among patients with extensive-stage small cell lung cancer treated with chemotherapy in the community oncology setting.
First Author: Jerome H. Goldschmidt
Poster
2022 ASCO Annual Meeting
Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC).
First Author: Eric Van Cutsem